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Abbreviations: ET-1 - Endothelin-1; IHD - ischaemic heart disease; ACh – acetylcholine, 41 
CFR – coronary flow reserve, CMD - coronary microvascular dysfunction, CMR - cardiac 42 
magnetic resonance, FFR - fractional flow reserve, INOCA - ischaemia with no obstructive 43 





































































the possibility of precision medicine using genetics to target oral ETA antagonist therapy in 69 
patients with microvascular angina. 70 
Keywords: Endothelin-1, single nucleotide polymorphism, stable angina pectoris, coronary 71 




































































Take home Figure 73 
74 
One sentence Summary 75 
A common genetic polymorphism previously linked with increased endothelin gene activity 76 
(rs9349379-G allele) is associated with increased ET-1 in microvascular angina patients and 77 
correlates with both invasive and non-invasive markers of coronary microvascular 78 
dysfunction including ischaemia on exercise treadmill testing and stress perfusion cardiac 79 





































































The coronary microcirculation has been implicated in the pathogenesis of angina for over 82 
fifty years, however disease mechanisms remain incompletely understood.1 Coronary 83 
microvascular dysfunction (CMD) is associated with adverse outcomes in angina and a 84 
plethora of other cardiovascular disorders.2-5 Standardised diagnostic criteria for 85 
microvascular dysfunction6 underpin recent studies which have identified the disease 86 
prevalence affecting two thirds of angina patients without obstructive epicardial coronary 87 
artery disease.7-10 These patients present a diagnostic and therapeutic challenge with up to 88 
one in four experiencing a major adverse cardiac event after five years of follow up.11, 12 The 89 
syndrome of ischemia and no obstructive coronary artery disease (INOCA) is particularly 90 
important in women,13 whose elevated cardiac risk is mostly driven by impaired coronary 91 
flow reserve (and not obstructive coronary disease).11 92 
Endothelin-1 (ET-1) is a highly potent endogenous vasoconstrictor of human coronary 93 
arteries14 and has been implicated in the pathogenesis of microvascular dysfunction.15, 16 ET-94 
1 mediated activation of the G protein-coupled ETA receptor on vascular smooth muscle cells 95 
induces endothelial dysfunction, inflammation and vasoproliferative effects. Circulating 96 
concentrations of serum ET-1 are inversely associated with coronary flow responses in 97 
patients with CMD.14, 16 Recently, a common (39%) genetic locus in chromosome 6p24 98 
(PHACTR1/EDN1) has been shown to be a distal regulator of endothelin gene expression.17 99 
The allele, rs9349379-G, is associated with an increased risk for atherosclerotic epicardial 100 
coronary artery disease and myocardial infarction.18  This functional single nucleotide 101 
polymorphism (SNP: rs9349379-G) is associated with increased endothelin gene expression 102 




































































ET-1 dysregulation is implicated in coronary vascular disease, however, the role of 104 
rs9349379 in the pathogenesis of CMD has not been examined. 105 
We determined association of the rs9349379-G allele with coronary microvascular 106 
dysfunction in angina patients undergoing invasive coronary function testing. Our secondary 107 
objectives were to investigate whether the G allele associates with non-invasive parameters 108 
of myocardial ischaemia. Our final objective was to examine vascular mechanisms using 109 
isometric tension recordings in small peripheral resistance vessels isolated from patients 110 
according to genotype. We evaluated ETA receptor mediated vasoconstriction in subjects 111 
according to rs9349379-G allele status. These included zibotentan, an ETA receptor-selective 112 






































































Study population 116 
We prospectively enrolled patients with stable angina. We screened elective adult referrals to 117 
two hospitals serving a population of ~2.5 million in the West of Scotland. Patients were 118 
scheduled to undergo clinically indicated invasive coronary angiography for the investigation 119 
of suspected coronary artery disease. The participants were enrolled into the Coronary 120 
Microvascular Angina (CorMicA) study (ClinicalTrials.gov: NCT03193294), which is a 121 
randomized, controlled, strategy trial of stratified medicine in angina patients without 122 
obstructive CAD19. The Rose-Angina questionnaire was administered on the day of the 123 
angiogram and only patients with definite or possible angina were eligible to participate.20 124 
Exclusion criteria included a non-coronary indication for invasive angiography e.g. valve 125 
disease, severe renal dysfunction (GFR<30 mL/min), inability to give informed consent and 126 
obstructive coronary disease determined during invasive coronary angiography (≥50% 127 
diameter stenosis and/or fractional flow reserve (FFR) ≤ 0.80). All coronary vasodilating 128 
drugs were discontinued at least 24 hours before the procedure. Pooled control genotype 129 
frequencies were ascertained from a contemporary medical genome reference cohort.21 130 
Definitions: coronary microvascular dysfunction 131 
We defined CMD using invasive coronary function testing and the Coronary Vasomotion 132 
Disorders International Study Group (COVADIS) diagnostic criteria.20 These physiological 133 
criteria included response to abnormal microvascular response to adenosine (raised IMR 134 
[≥25]) and/or abnormal CFR [<2.0]). In addition, CMD also included subjects with 135 
microvascular spasm during ACh provocation (reproduction of angina symptoms, ischaemic 136 




































































testing).22 CMD is frequently associated with epicardial vasospasm and hence patients with 138 
abnormal vasoreactivity during adenosine assessment (abnormal IMR and/or CFR) and 139 
coexistent epicardial vasospasm during ACh provocation were included within the CMD 140 
group. FFR was measured to rule-out flow limiting coronary artery disease as an alternative 141 
explanation for myocardial ischaemia (INOCA subjects had FFR >0.8 in target artery). 142 
Measurement of coronary vascular function in vivo 143 
We used an interventional diagnostic procedure (IDP) that combined guidewire-based direct 144 
measurement of coronary vascular function followed by pharmacological vasoreactivity 145 
testing. Specifically, the IDP included a guidewire-based measurement of coronary vascular 146 
function (FFR, coronary flow reserve [CFR], and the index of microvascular resistance 147 
[IMR]) followed by pharmacological vasoreactivity testing with acetylcholine (ACh) and 148 
glyceryl trinitrate (GTN) and has been previously described.19, 23 149 
In brief, an intravenous infusion of adenosine (140 μg·kg−1·min−1) was administered via a 150 
large peripheral vein to induce steady-state maximal hyperaemia for a period of at least 90 151 
seconds with a target time of 180 seconds. A pressure-temperature sensitive guidewire was 152 
placed into the distal third of a major epicardial coronary artery (typically the left anterior 153 
descending [LAD]). The myocardial FFR was calculated by the ratio of mean distal coronary 154 
pressure to mean aortic pressure at maximal hyperaemia. A FFR ≤0.80 was taken as 155 
abnormal and indicative of flow-limiting coronary artery disease.24 CFR was calculated using 156 
thermodilution as resting mean transit time divided by hyperaemic mean transit time.25 A 157 
CFR <2.0 was defined as abnormal representing impaired vasodilator reserve.26 The IMR 158 
was calculated as the product of mean hyperaemic transit time and mean distal coronary 159 




































































microcirculatory resistance.28 These invasive parameters were simultaneously derived in real-161 
time using dedicated software (Coroventis, Uppsala, Sweden). We assessed endothelium-162 
dependent coronary vasomotor function using intra-coronary infusions of ACh via the 163 
guiding catheter at concentrations of 0.182, 1.82, and 18.2 µg/mL (10-6, 10-5, and 10-4 mol/L, 164 
respectively) at 1 mL/min for 2 minutes via a mechanical infusion pump.29 Patients who had 165 
CMD (e.g. abnormal CFR and/or IMR) but co-existent epicardial vasospasm during 166 
acetylcholine bolus (100μg bolus of ACh; 5.5 mL of 10-4 mol/L over 20 seconds) were 167 
considered in the CMD group.30 In order to assess non-endothelial dependent vasodilatation, 168 
300 µg of GTN was administered by manual intra-coronary bolus injection. Detailed methods 169 
are reported in the online appendix. 170 
Blood and tissue analysis 171 
Serum ET-1 was determined using blood obtained on the day of coronary function testing 172 
(Quantikine ® ELISA, R&D Systems® Europe, Abington [UK]). Blood was obtained from 173 
participants following an overnight fast in a recumbent position. 174 
Ex vivo pharmacological assessment of peripheral vascular function was performed on 175 
patients who volunteered to undergo a gluteal skin fat biopsy within 4 weeks of the invasive 176 
coronary function assessment. The biopsy was obtained under sterile conditions using local 177 
anaesthesia with lidocaine (2%). Small peripheral resistance vessels (< 400µm) were 178 
carefully dissected from fresh biopsies using a light microscope. 2mm length vessels were 179 
mounted on 40-μm stainless steel wires for isometric myography in multi-channel myograph 180 
chambers (DMT, Denmark) filled with physiological saline solution. Isometric tension 181 
recordings followed-on directly using the technique of wire myography to study small 182 
peripheral resistance arteries with paired cumulative concentration response curves (CCRCs) 183 




































































(AstraZeneca, U.K.; Open Innovation). This vascular biology sub study was an extension of 185 
previous work in INOCA subjects that was previously published in this journal.31 The 186 
detailed methods are described in the study appendix. The peripheral vascular sensitivity to 187 
ET-1 (pEC50) and maximum vasoconstriction to ET-1 (Emax) were determined. 188 
For the antagonist studies the affinity (KB) of BQ123 was first determined in paired vessels 189 
from individuals and calculated using Schild regression. The pKB (-log10 KB) values were 190 
compared between each genotype as an indicator of whether or not patients of different 191 
genotypes are likely to respond equally well to an ETA antagonist used clinically. A final 192 
series of experiments involved paired vessel experiments using ET-1 CCRCs in the presence 193 
and absence of a highly selective ETA receptor antagonist, zibotentan to determine a pKB 194 
value and assess whether zibotentan could reverse an established ET-1 mediated vessel 195 
constriction. 196 
Cardiac magnetic resonance imaging and ischaemia testing protocol 197 
Patients were prospectively invited to undergo quantitative perfusion cardiac magnetic 198 
resonance (CMR) imaging at 1.5 Tesla using pharmacological stress testing with intravenous 199 
adenosine (140 µg/kg/min) within 6 weeks of the index coronary angiogram. CMR studies 200 
were performed using a standardized CMR protocol (Siemens MAGNETOM Avanto, 201 
Erlangen, Germany). The CMR scans were interpreted by two experienced observers (Level 202 
III accreditation, European Society of Cardiovascular Imaging) blind to diagnostic findings 203 
and genotype. The raw stress and rest perfusion images were qualitatively assessed for 204 
inducible or fixed perfusion defects. The perfusion was classified as either normal, abnormal, 205 
or equivocal. If a perfusion defect was present, it was reported as having and epicardial, 206 




































































according to the American Heart Association 16-segment model32, and were classified 208 
according to the transmurality of the perfusion defect (<50 % or >50%), and the number of 209 
segments with qualitatively abnormal perfusion was defined. Dark rim artefact was 210 
adjudicated based on standardised criteria.33 211 
The first-pass perfusion images were then post-processed to derive quantitative pixel 212 
perfusion maps to derive absolute myocardial blood flow (MBF) and myocardial perfusion 213 
reserve (MPR) (further detail in Supplementary information).34 214 
Treadmill exercise stress electrocardiography using the Bruce protocol was analysed from the 215 
sub-group of patients who had been pre-selected for this procedure on clinical grounds prior 216 
to invasive coronary angiography. We used the Duke treadmill score (DTS) which is a 217 
validated metric with established prognostic cardiovascular utility.35 The exercise treadmill 218 
test analysis included (1) exercise duration and (2) the Duke Treadmill Score36 by a 219 
cardiology researcher (EY) blinded to genotype and invasive physiology. The DTS is based 220 
on the occurrence of angina during treadmill exercise testing, ST-segment depression during 221 
the test and peak exercise duration (or METS achieved). Specifically, the DTS equals the 222 
maximum exercise time in minutes – (5 × the maximal net ST-segment deviation in mm 223 
during or after exercise) – (4 × the treadmill angina index (where 0 = no angina, 1 = non-224 
limiting angina, 2 = exercise limiting angina). 225 
All subjects were asked to abstain from caffeine-containing beverages or foodstuffs for 24 226 
hours, and vasoactive medications for 48 hours prior to the CMR examination. All scan 227 
acquisitions were spatially co-registered. All CMR analyses were performed by a blinded 228 




































































Statistical analysis 230 
The main hypothesis in our study was that regulation of ET-1 gene expression reflected by the 231 
presence of the intronic ET-1 gene enhancer, rs9349379 G, associates with invasive tests of 232 
CMD. We tested the association of genotype (SNP rs9349379 G-A allele status) with CMD on 233 
invasive coronary vasoreactivity testing by calculating the odds ratio (OR) and its 95% 234 
confidence intervals (CI). Multivariable logistic regression was used to determine whether 235 
genotype was independently associated with CMD (as defined by abnormal response to 236 
intracoronary ACh and/or systemic adenosine) adjusting for overall cardiac risk (ASSIGN 237 
score) including previous cardiac events.37 238 
Categorical data are presented as percentages and continuous parameters are shown as means 239 
with SD values or medians with interquartile ranges. For secondary analyses, subjects were 240 
divided into three genotype groups. Kruskal-Wallis test was used to test whether distribution 241 
of non-parametric variables is the same between the groups. Subgroup analysis of A versus G 242 
genotypes was determined a priori to evaluate any differences between the two most 243 
differentiated groups. The least-squares (LS) mean of serum ET-1 levels was compared 244 
between the groups derived using analysis of co-variance with serum ET-1 as dependent 245 
variable and adjusted for age, sex, BMI, genotype and cardiovascular risk as covariates and 246 
possible confounders. Linear associations with invasive and non-invasive metrics of 247 
microvascular disease were performed by analysis of variance [ANOVA] with P for linear 248 
trend for continuous parameters and χ2 test with P for linear-by-linear test for categorical 249 
variables. Statistical analyses were performed with Prism 7.0 (GraphPad, La Jolla, CA) and 250 





































































We prospectively enrolled three hundred and ninety-one patients with angina between 253 
25/11/2016 - 11/12/2017 at two hospitals serving a population of ~2.5 million in the West of 254 
Scotland (CorMicA: ClinicalTrials.gov NCT03193294).19 Invasive coronary angiography 255 
revealed obstructive disease in 206 (53.7%) participants who were then excluded from further 256 
study. One hundred and fifty-one participants with no obstructive coronary disease continued 257 
in the study (Figure 1, Table 1). Evidence of CMD was found in 109 (72%) of 151 subjects 258 
undergoing invasive coronary vasoreactivity testing (Table 2). An overview of the study and 259 
investigations is illustrated in Figure 1. Genetic analysis was completed in 140 subjects 260 
(93%) using baseline venous blood samples. The mean age of patients in this analysis 61.1 261 
±10.1 years. There was a predominance of women (103 [74%]) and the estimated 10-year 262 
risk of cardiovascular events (ASSIGN) was appreciable at 25% (± 20). 263 
The genotype distribution of rs9349379 was AA (N=50, 36%), AG (N=51, 36%), GG (N=39, 264 
28%). This SNP did not fulfil Hardy Weinberg equilibrium (P=0.0015) reflecting biologic 265 
ascertainment of genotypes. One hundred and forty subjects underwent genetic analysis for 266 
(rs9349379 G allele) with an allele frequency of 46% (129/280 alleles). The allele frequency 267 
was increased in our angina cohort compared to that of genome bank control subjects 268 
(rs9349379-G allele frequency 39% [5551/14380]; Chi squared = 6.15, P=0.013).21 The 269 
rs9349379-G allele was associated with over double the odds of CMD (OR 2.33; 95% CI 270 
1.10 – 4.96; P=0.027; Figure 2A). Subjects with G allele had higher circulating serum ET-1 271 
concentration (LS mean 1.59pg/ml versus 1.28pg/ml; difference 0.31pg/ml; 0.10 to 0.52; 272 
P=0.005; Figure 2B). Each additional G allele was linearly associated with CMD on invasive 273 
interrogation (Figure 3A; P=0.021). On multivariable analysis, the G allele remained 274 




































































Considering diagnostic subtypes of microvascular dysfunction, the vast majority had CMD 276 
during adenosine interrogation (73% abnormal CFR and/or IMR) and only 27% of the 277 
genotyped population had isolated microvascular spasm (isolated CMD to ACh only). There 278 
was a statistically significant relationship between genotype and coronary microvascular 279 
dysfunction, as reflected by an impaired coronary vasodilator reserve (abnormal CFR: AA 280 
20%, AG 35%, GG 41%; Figure 3B; P=0.030). A similar relationship was noted for 281 
prevalence of abnormal microvascular resistance in each genotype (abnormal IMR: AA 24%, 282 
AG 33%, GG 46%; Figure 3C; P=0.029).  CFR decreased linearly with each additional 283 
rs9349379-G allele (AA 3.0 (2.1, 3.7); AG 2.7 (1.8, 3.5); GG 2.1 (1.7, 3.2); overall P=0.046; 284 
Figure 3D; Table 2). The highest risk group (GG) had a significantly lower CFR than the AA 285 
group (median difference 0.84, 95% CI 0.1 – 1.1). The prevalence of abnormal invasive 286 
acetylcholine response was not statistically different between the groups (any G allele 36% 287 
versus no G allele 30%, P=0.463). Patients with isolated CMD to ACh (microvascular spasm) 288 
had similar ET-1 levels to those without (1.33ng/ml v 1.28ng/ml; P =0.769). The highest 289 
serum ET-1 levels were seen in subjects with concordant abnormalities in both CFR and IMR 290 
with linear stepwise reduction compared to those with only one index of CMD and lowest in 291 
those without any abnormalities (mean 1.67ng/ml (both) v 1.39ng/ml (one) v 1.31ng/ml 292 
(none); P trend = 0.041). 293 
The Gensini angiographic score reflecting the extent (or burden) of coronary atherosclerosis 294 
was higher in the rs9349379-GG group (median score 1.0, [0.0, 6.0]) compared to the AA 295 
group (median score 0.0, [0.0, 2.0]; P=0.037; Table 2). As might be expected in this 296 
population of INOCA patients, the physiological burden of epicardial coronary artery disease 297 
was similar between the groups (myocardial fractional flow reserve (FFR), AA 0.88 (±0.05); 298 




































































One hundred and seven subjects underwent an adenosine stress perfusion cardiac MRI within 300 
6 weeks of the invasive angiogram. Forty-six (43%) patients had evidence of a sub-301 
endocardial circumferential abnormality of myocardial perfusion attributable to CMD (Table 302 
2). The rs9349379-G allele was associated with abnormal myocardial perfusion disclosed by 303 
stress perfusion MRI (AA 31%, AG 43%, GG 56%; P=0.042, Figure 4A).  The association of 304 
genotype with CMD was more robust when considering subjects with either a circumferential 305 
subendocardial perfusion defect disclosed by MRI or invasive evidence of CMD, (AA 65%, 306 
AG 85%, GG 91%; P<0.001; Figure 4B). The absolute global and subendocardial perfusion 307 
reserve (MPR) was numerically lower with each G allele however the differences were not 308 
statistically significant (Table 2; Figures 4C & 4D). 309 
We then assessed relationships between exercise treadmill testing, invasive measures of 310 
coronary vascular function and genotype. Ninety subjects prospectively completed exercise 311 
treadmill testing during standard care diagnostic work up prior to invasive coronary 312 
angiography, eighty-four of these subjects were included in the study with the remainder 313 
being excluded due to lack of genotype data. The mean exercise duration was 367 (± 156) 314 
seconds and similar between the groups (Table 2). The mean Duke Treadmill Score (DTS) 315 
was -1.0 (± 5.3) units. The presence of CMD was associated with reduced DTS (CMD -2.3 v 316 
No CMD +3.5; Difference -5.8 units, 95% CI -8.2 to -3.3; P<0.001; Figure 4E). Overall, 317 
there was a moderate inverse correlation between presence of CMD and the DTS 318 
(Spearman’s Rho = -0.42; P<0.001). Considering the cohort of eighty-four patients in whom 319 
genotype and DTS were both available, there was a lower DTS for each additional G allele 320 
consistent with increasing ischaemia with ET-1 gene enhancement. A priori analysis of high-321 
risk subjects (homozygous for the minor G allele) compared to the AA group revealed a 322 
mean difference of -3.0 units in DTS (95% CI -5.8 to -0.1; P=0.045; (Figure 4F). There was a 323 




































































(Spearman’s rho -0.21; P=0.055), that was not statistically significant. The angina index 325 
during exercise was linearly associated with G allele status (non-limiting or limiting angina 326 
AA 59% v AG 68% v GG 87%; P trend =0.036). The exercise time was not significantly 327 
lower amongst subjects with the G allele (365 v 392 seconds; P=0.423). 328 
Sixty-eight genotyped subjects agreed to participate in a vascular biology sub study, 329 
providing written informed consent for a gluteal subcutaneous biopsy within 4 weeks of 330 
coronary angiography. Subjects who volunteered to have a biopsy were of similar age and 331 
cardiac risk to those who declined to participate in the sub study (biopsy participants mean 332 
age 62 ± 9 years v 61 ± 11 years (P=0.134), ASSIGN score 23% ± 18 v 28% ± 23 (P=0.198). 333 
Forty-four (65%) of these patients had biopsies with a sufficient number of small arteries to 334 
undergo paired cumulative concentration response curves (CCRCs) to ET-1 in the presence 335 
and absence of an ETA receptor antagonist, either BQ123 or zibotentan (ZD4054; 336 
AstraZeneca, Cambridge, UK). Grouping according to genotype (AA, n=16; AG, n=14; GG, 337 
n=14), vasodilator responses to ACh (ACh Emax) were similar (Table 3). Similarly, vessels 338 
had similar potency for ET-1 (pEC50 AA 9.34, AG 9.45 and GG 9.32; P=0.533) and 339 
maximum vasoconstriction to ET-1 (Emax AA 122.3%, AG 115.5%, GG 129.7%; P=0.533; 340 
Figure 5A; Table 3). 341 
Notably, the selective ETA receptor antagonist, BQ123, caused a parallel rightward shift of 342 
the CCRC with comparable pKB values between groups AA, AG and GG (pKB values of 7.07 343 
[± 0.23], 7.79 [± 0.35] and 7.41 [± 0.26] respectively; P=0.209; Figure 5B). Zibotentan, 344 
ahighly selective orally active ETA receptor antagonist, attenuated the constrictor response to 345 
ET-1 with pKB of 7.54 (95% CI 7.27 – 7.82), comparable to that of BQ123 pKB 7.53 (95% CI 346 




































































Crucially, these studies confirmed that zibotentan produced a concentration-dependent 348 
inhibition of an established constrictor response to ET-1 and was still efficacious in subjects 349 
with G allele (P<0.001; Figure 5C). Figure 6 shows representative investigations from a 350 
female subject with few traditional cardiovascular risk factors but high-risk ET-1 enhancer 351 





































































We identify a novel genetic risk locus for coronary microvascular dysfunction. Our study 354 
extends a report from the WISE investigators on genotype associations with arterial 355 
vasomotion.13 Our results support the hypothesis that dysregulation of the ET-1/ ETA receptor 356 
system underpins abnormalities in the coronary microcirculation leading to myocardial 357 
ischaemia. Firstly, rs9349379-G allele status is associated with higher serum ET-1 and the 358 
presence and extent of CMD in patients with angina but without obstructive coronary disease. 359 
Secondly, the genetic polymorphism associates with ischaemia testing using distinct, non-360 
invasive modalities including exercise stress electrocardiography and stress perfusion CMR. 361 
Thirdly, we demonstrate in ex vivo human small peripheral resistance vessels isolated from 362 
affected patients, that the ETA vasoconstrictor response is not downregulated in the presence 363 
of increases in endothelin gene expression and ET-1 activity in patients with the rs9349379 G 364 
allele. Finally, we provide proof-of-concept mechanistic data supporting a role for zibotentan, 365 
an orally active highly selective ETA receptor antagonist, in reversing established ET-1 366 
mediated vasoconstriction. These findings have potential clinical relevance since zibotentan 367 
is available for repositioning as a novel, disease-modifying therapy in this patient population. 368 
The results of our study support the rationale for the ‘Precision Medicine with Zibotentan in 369 
Microvascular Angina (PRIZE)’ trial involving gene testing for the SNP rs9349379 and 370 
linked therapy (ClinicalTrials.gov Identifier: NCT04097314). 371 
Endothelin dysregulation 372 
Pre-clinical studies in experimental models of CMD implicate increased cardiac ET-1 373 
production leading to endothelial dysfunction, enhanced vascular expression of rho-kinases 374 
and reactive oxidant species such as superoxide and enhanced ET-1-mediated 375 




































































dysfunction is a systemic phenomenon characterised by peripheral endothelial dysfunction 377 
and enhanced peripheral small vessel vasoconstriction.31, 39 Further, impaired coronary 378 
microvascular function and the propensity to myocardial ischaemia may increase longer 379 
term-risk of major adverse cardiac events (MACE).40, 41 Our study is distinct and builds on 380 
our prior vascular studies of ET-1 in microvascular angina as we used zibotentan which has 381 
more potential for clinical translation requiring future phase II studies.31 In addition, subjects 382 
were analysed by ET-1 rs9349379-G allele status rather than presence or absence of CMD. 383 
We observed that chronic exposure to increased circulating concentrations of ET-1, as 384 
reflected by rs9349379-G allele status, did not lead to downregulation to ETA mediated ET-1 385 
vasoconstriction in patients with microvascular angina. The converse SNP (rs9349379-A) 386 
was recently found to be associated with spontaneous coronary artery dissection (SCAD) 387 
which typically occurs in patients without atherosclerosis.21 This finding is consistent with 388 
our work, particularly given that microvascular function is typically normal in SCAD.42 389 
We showed that rs9349379-G allele was associated with higher serum ET-1 levels which is 390 
consistent with previous studies whereby the SNP associates with higher levels of ET-1 and 391 
its precursor (Big ET-1) in healthy subjects. Interestingly, the ET-1 plasma concentration in 392 
our INOCA population is comparable to ET-1 plasma concentrations in other conditions 393 
including pulmonary artery hypertension43 but lower than in other INOCA cohorts.44 We 394 
acknowledge that abluminal secretion of ET-1 away from endothelial cells toward underlying 395 
vascular smooth muscle means circulating concentrations of ET-1 are an imperfect measure 396 
of ET-1 activity in vascular tissues.45 Chronic elevation of circulating ET-1 may lead to 397 
adaptive down-regulation of its endogenous G-protein coupled receptors. This phenomenon 398 
has been described for ETA receptors in mice in which the clearing ETB receptor has been 399 
knocked out.46 The baseline blood pressure was similar between the groups in our study 400 



































































an inverse association with systolic blood pressure.17 This is particularly interesting given its 402 
association with atherogenesis and CAD. It is thought that excess ET-1 effects healthy 403 
populations mediate hypotension via hypotension via ETB -induced nitric oxide and 404 
prostacyclin production, resultant vasodilation, diuresis, and natriuresis.47 Our study was 405 
underpowered to determine significant differences between baseline blood pressures which 406 
may also be obfuscated by previous treatment for hypertension in the groups. 407 
Microvascular angina is a chronic, debilitating condition of unmet therapeutic need. The 408 
vascular pharmacology findings in our clinical study indicate that despite a genetic 409 
predisposition to enhanced endothelin gene expression based on the rs9349379-G allele 410 
status, potentially leading to lifelong enhanced exposure to circulating concentrations of ET-411 
1, the net effect on ET-1 response or sensitivity to ETA antagonists was similar between the 412 
groups by rs9349379 allele status. This result indicates that the ETA receptor may not be 413 
downregulated in affected patients raising the potential for health gain by treatment with a 414 
selective ETA receptor antagonist, such as zibotentan. Importantly, BQ123 fully blocked the 415 
constrictor responses in all of the groups. Our vascular pharmacology study was specifically 416 
focused on the relationships between the rs9349379-G allele status, ET-1 vasoactive 417 
responses and ETA receptor blockade. Patients with microvascular angina may have similar 418 
tissue responses to oral ETA receptor blocker therapy – this important possibility merits 419 
further (NCT04097314). 420 
In a mechanistic, randomized, controlled trial in patients with microvascular angina, Johnson 421 
and Gould reported that ETA receptor antagonism increased (improved) the homogeneity of 422 
resting myocardial perfusion.48  Their study used cardiac positron emission tomography 423 
(PET) to quantify the homogeneity index (a visual notion of homogeneity derived from 424 




































































circulating concentrations of  ET-1 which in turn was associated with increased coronary 426 
vascular resistance and impaired coronary blood flow.50 Recently, Theuerle et al have shown 427 
that plasma ET-1 is associated with invasive CMD in a 32 INOCA patients, however the 428 
relationship was driven by elevated microvascular resistance and not coronary flow reserve.51 429 
Limitations 430 
We describe compelling mechanistic evidence for a functional SNP being linked to CMD. 431 
We have followed accepted guidelines for CMD classifications, but it is recognized there are 432 
caveats with any classification system and acknowledge these are also relevant to this study. 433 
Firstly, we adopted binary cut-offs for the IDP test. It is possible that indeterminate (grey-434 
zone or borderline) test results may have misclassified some patients. Furthermore, patients 435 
with CMD were heterogenous and we aggregated patients with different types of 436 
microvascular dysfunction e.g. impaired flow reserve, increased microvascular resistance, 437 
abnormal acetylcholine response. Nonetheless, the vascular phenotype of affected patients 438 
was of coronary vascular dysfunction based on consensus guidelines for abnormal coronary 439 
microvascular response during systemic adenosine, an abnormal vasomotor response to 440 
intracoronary Ach, or both.6 In support of this approach, we observed a strong linear 441 
relationship between CMD and non-invasive ischaemia testing on the exercise treadmill 442 
(Figure 4F). In addition, heterogeneity is the rule rather than exception when considering 443 
many similar cardiovascular disorders, for example heart failure with preserved ejection 444 
fraction.52 Our stratified sensitivity analysis by CMD type i.e. structural microvascular 445 
disease (i.e. raised IMR) and impaired vasodilator reserve (reduced CFR) (Table 2) lend 446 
further support to the design of our translational study. Secondly, not all patients underwent 447 
all testing and the exercise treadmill tests were not performed in a core-lab and were 448 




































































protocol and the results were determined in a standardised manner, blinded to rs9349379 450 
allele status. Treadmill exercise testing is an imperfect measure of ischaemia and hence it is 451 
plausible that the known association of the rs9349379-G allele with epicardial CAD is a 452 
confounding factor. Johnson and Gould recently highlighted how flush ostial branch vessel 453 
occlusion may account for ischaemia despite a visual “normal” angiogram without stenosis.53 454 
On the other hand, the Duke Treadmill Score has a mature associated literature with proven 455 
utility in CMD patients.54, 55 The relatively small sample size and possibility of unmeasured 456 
baseline differences increases the possibility of type I error. Thirdly, we administered intra-457 
arterial doses of short acting GTN (100-200 micrograms) to facilitate procedure safety 458 
relating to transradial access, coronary arteriography and invasive coronary vasoreactivity 459 
testing. Theoretically, GTN may affect the vascular responses to ACh however the half-life 460 
of GTN is around two minutes. Hence, after 10 minutes, only 3% of the GTN dose is 461 
bioavailable and we think the potential for confounding and a false negative test for 462 
microvascular vasospasm is unlikely. Conversely, a positive ACh test confounds assessment 463 
of true resting flow and may lead to falsely lowered CFR and hence we support ACh testing 464 
after adenosine assessment. Finally, we compared the allele prevalence within our cohort 465 
from Scotland with a pooled multicentre contemporary medical genome reference group of 466 
controls. Our study would have been strengthened by a control comparator group from the 467 
same area and ethnic background as our subjects. Further, although the SNP did not fulfil the 468 
Hardy-Weinberg equilibrium for the population as a whole, the control group from this study 469 
without CMD was consistent with the equilibrium (Chi square 2.99, P=0.084). It is plausible 470 
that HW was not met in the CMD group due to its association with the rs9349379 G allele of 471 
interest. This study is a cross-sectional analysis of a single genetic locus and provides 472 





































































Clinical translation 475 
These observations hypothesis generating particularly given the small sample size and 476 
heterogeneous patient population. The findings require external validation in other CMD 477 
cohorts whilst future work in populations from different regions would provide helpful 478 
context. 479 
Overall, our study supports the case for selective ETA blockade distinct from ETB modulation 480 
in patients with microvascular disease in the heart. Oral ETA-selective blockade has 481 
therapeutic potential by attenuating the propensity to microvascular vasospasm, increasing 482 
coronary blood flow, and further improving coronary endothelial function through NO-483 
mediated release.56 Zibotentan is one compound that holds promise as the most ETA selective 484 
of all orally active ETA receptor antagonists,  which makes it particularly suited to use in 485 
microvascular angina. A targeted approach using selective ETA receptor antagonist therapy in 486 





































































We identified a genetic risk locus for coronary microvascular dysfunction. The common 489 
genetic polymorphism (SNP rs9349379-G allele) was associated with higher ET-1 and both 490 
invasive coronary microvascular dysfunction and non-invasive tests for ischaemia in subjects 491 
with angina but no obstructive CAD.  Mechanistic ex-vivo studies confirmed subjects with 492 
this functional allele have preserved response to ETA receptor blockade. Zibotentan, an orally 493 
active ETA receptor antagonist, reversed an established ET-1 mediated vasoconstriction. This 494 
study offers hope for angina patients although future trials are needed to determine whether 495 
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conditions associated with vasospasm. This suggests that ETA receptor antagonism in this 737 





































































Fig. 3 – Genotype: phenotype association of G allele with invasive coronary 750 
microvascular dysfunction 751 
752 
 A - C The prevalence of microvascular dysfunction detected during invasive coronary testing was 753 
associated with genotype status (AA 60%, AG 75%, GG 83%; P=0.021). Presence of abnormal 754 
coronary flow reserve and microcirculatory resistance were linearly associated with each additional 755 
G allele. P-value represents Pearson-Chi square test for linear trend (categorical data). 756 
D - Coronary flow reserve (CFR) was lower amongst subjects with two high risk G alleles 757 
(rs9349379) consistent with detrimental effects of increased Endothelin gene expression on the 758 



































































































































































analysis (AA v GG group – solid line) showed lower CFR in the GG group (P=0.013). Data is 760 




































































Fig. 4 - Genotype: phenotype association of G allele with non-invasive ischaemia testing 762 
763 
A - Cardiovascular Stress Magnetic Resonance Imaging at 1.5 Tesla (N=107). There was a linear 764 
relationship between the G allele and presence of an inducible perfusion defect on CMR (χ2 test for 765 
linear trend P=0.042). 766 
B – The relationship was more robust when considering with invasive evidence of CMD and/or 767 
inducible perfusion defect. Over 90% of GG subjects had at least one abnormality compared with 768 
only 65% of AA subjects (P<0.001) 769 
C & D – Myocardial perfusion reserve was numerically reduced in AG and GG subjects compared to 770 
AA subjects however this was not statistically significant (P value represents ANOVA test for trend). 771 

















































































































































































































E – Invasive evidence of microvascular dysfunction (defined by abnormal response to intracoronary 773 
ACh and/or systemic adenosine) was functionally significant and associated with ischaemic burden 774 
on symptom limited exercise treadmill testing (CMD -2.3 v No CMD +3.5; Difference -5.8 units; -775 
8.2 to -3.3; P<0.001). 776 
F - Exercise Treadmill Testing (n=84) – There was a relationship between genotype group and 777 
worsening ischaemia on stress testing (ANOVA P trend=0.045). The mean difference in ischaemia 778 
by DTS between group GG and group AA was -3.0 units (95% CI -5.8 to -0.1; P=0.045). Error bars 779 





































































B – Antagonist potency of novel therapeutic oral ETA receptor antagonist zibotentan (N=8, 789 
mean 7.54 [95% CI 7.27-7.82]) is similar to peptide antagonist BQ123 (N=27, mean 7.53 790 
[95% CI 7.37-7.69]). Higher pKB represents a higher antagonist potency. 791 
C - Zibotentan: reversal of established ET-1 vasoconstriction. Proof of concept dose 792 
dependent reversal of potent and established ET-1 mediated peripheral arteriolar 793 
vasoconstriction. Crucially, the highest concentration tested which is also the plasma 794 
concentration achieved by a clinically relevant dose of 10 mg/day rapidly and fully reversed 795 
the established ET-1 constrictor response, indicative of efficacy in conditions of vasospasm.  796 
Comparison using ordinary two-way ANOVA including time and dose both significant 797 





































































enhancer genotype. Maximum ST represents the maximum planar or down sloping ST 803 
segment depression during the exercise treadmill test. Invasive coronary angiography of both 804 
subjects is near identical showing only minimal luminal irregularities. White arrows represent 805 
subendocardial inducible ischaemic myocardium during adenosine stress MRI in a patient 806 
with severe coronary microvascular dysfunction. Ex vivo vascular biology (bottom panel) 807 
shows typical ET-1 mediated vessel constriction during wire myography. Increasing vessel 808 
tension corresponds to the rising curve at each dose titration. A paired identical vessel 809 
experiment is performed after incubation with BQ123, an ETA receptor antagonist. This curve 810 
is marked in blue, the curve of ET-1 response is shifted to the right indicating that the ETA 811 
receptor mediates vasoconstriction. Despite the ET-1 gene enhancer, the GG subject does not 812 
appear to have ETA receptor downregulation with similar levels of antagonist potency. This 813 
supports that ETA receptor antagonism in this group of patients may have therapeutic benefit. 814 
CFR: coronary flow reserve, FFR: fractional flow reserve, IMR: index of microcirculatory 815 


































































Table 3 – Pathophysiology: vascular biology of ET-1. 
SNP (rs9349379) genotype (n=44) 
AA (N=16) AG (N=14) GG (N=14) P-value* 
Vessel Diameter (um) 344 (±88) 342 (±89) 347 (±125) 0.851 
Vessel Length (mm) 1.85 (±0.12) 1.87 (±0.10) 1.82 (±0.11) 0.276 
ACh Emax (%) 77.7 (52.9 – 97.8) 80.2 (59.9 – 97.6) 92.5 (57.8 – 99.1) 0.696 
ACh pEC50 7.28 (6.88 - 7.82) 7.26 (6.82 - 8.00) 6.96 (6.84 – 7.44) 0.308 
ET-1 Emax (%) 122.3 (115.7 - 134.7) 115.5 (107.5 - 125.2) 129.7 (115.8 - 151.2) 0.533 
ET-1 pEC50 9.34 (9.15 - 9.52) 9.45 (9.24 - 9.67) 9.32 (8.96 - 9.69) 0.533 
BQ123 pKB [± SEM] 7.07 [±0.23] 7.79 [±0.35] 7.41 [±0.26] 0.209 
Forty-four (65%) of 68 patients who underwent invasive biopsies had a sufficient number of small arteries to undergo paired cumulative 
concentration response curves (CCRCs) to ET-1 in the presence and absence of an ETA receptor antagonist. Data are mean (± SD) or mean 
(95% CI for pooled best fit CCRC). CCRC: cumulative concentration response curves were drawn with best-fit derived values. pKB data 
involved paired vessels undergoing ET-1 CCRC in the presence or absence of BQ123 ETA receptor antagonist (available in 37 out of the 44 
subjects: AA N=14; AG N=10; GG N=13). *Significance determined using ANOVA for normally distributed means, Kruskal-Wallis test used 
for between group comparison of non-parametric variables and Extra-Sum of squares F test (for CCRC pooled best fit ET-1 data). There were 





































































Left ventricular mass – (indexed, mL/m2) 42.0 (±7.0) 42.3 (±8.1) 42.1 (±7.8) 0.924 
Data are mean (± SD), median (IQR) or N (%). CAD= coronary artery disease. CFR = 
coronary flow reserve. FFR = fractional flow reserve. LVEDP = left ventricular end-diastolic 
pressure. IMR = index of microcirculatory resistance.  ‡ denotes core-laboratory adjudication 
of any angiographic evidence of coronary atherosclerosis including any minimal 
angiographic luminal irregularity. †Gensini angiographic score is a metric of angiographic 
disease severity incorporating lesion severity and location. METS: metabolic equivalent of 
task. Detailed MRI methodology available in online appendix. * P-value represents between 
group ANOVA for linear trend (continuous data) or Pearson-Chi square test for linear trend 
(categorical data), Kruskal-Wallis test of probability that the distribution of non-parametric 








































































Supplementary Information (Appendix) 
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1. Supplementary Figure 1 – ET-1 in CMD subjects
A: Serum ET-1was higher in patients with coronary microvascular dysfunction than 
normal control subjects [P=0.040]. ET-1 was adjusted for baseline confounders in 
regression model outlined in study methods. B: Normalized serum ET-1 (Log 
transformed) showed a trend towards significance with increasing peptide linearly with 








































































































4. Supplementary Table 1. Genotype as multivariable
predictor of CMD 
B OR Lower CI Upper CI P-value 
Genotype (per G allele) 0.84 2.31 1.08 4.91 0.030 
ASSIGN 0.00 1.00 0.98 1.02 0.970 
Past CV event 0.23 1.26 0.51 3.15 0.619 
Multivariable predictors of any CMD (N=109) with three baseline factors in model listed 
above. The fitted regression model showed moderate discrimination potential with an 
AUC of 0.647 (95% CI 0.544 – 0.750; P=0.007). ASSIGN refers to estimated 10-year risk of 




































































5. Supplemental Methods: Measurement of coronary
vascular function in vivo 
We used an interventional diagnostic protocol that combined guidewire-based direct 
measurement of coronary vascular function followed by pharmacological vasoreactivity 
testing. Specifically, the procedure included a guidewire-based measurement of coronary 
vascular function (FFR, coronary flow reserve [CFR], and the index of microvascular 
resistance [IMR]) followed by pharmacological vasoreactivity testing with acetylcholine 
(ACh) and glyceryl trinitrate (GTN) and has been previously described.2, 3 
In brief, an intravenous infusion of adenosine (140 μg·kg−1·min−1) was administered via a 
large peripheral vein to induce steady-state maximal hyperaemia. A pressure-temperature 
sensitive guidewire was placed into the distal third of a major epicardial coronary artery 
(typically the left anterior descending [LAD]). The myocardial FFR was calculated by the 
ratio of mean distal coronary pressure to mean aortic pressure at maximal hyperaemia. A 
FFR ≤0.80 was taken as abnormal and indicative of flow-limiting coronary artery 
disease.4 CFR was calculated using thermodilution as resting mean transit time divided 
by hyperaemic mean transit time.5 A CFR <2.0 was defined as abnormal representing 
impaired vasodilator reserve.6 The IMR was calculated as the product of mean 
hyperaemic transit time and mean distal coronary pressure at hyperaemia.7 An IMR >25 
was defined as abnormal and indicative of increased microvascular resistance.8 These 
invasive parameters were simultaneously derived in real-time using dedicated software 
(Coroventis, Uppsala, Sweden). We assessed endothelium-dependent coronary vasomotor 
function using intra-coronary infusions of ACh via the guiding catheter at concentrations 



































































2 minutes via a mechanical infusion pump.9 We then immediately performed provocation 
testing for microvascular or epicardial coronary artery spasm using a 100μg bolus of ACh 
(5.5 mL of 10-4 mol/L over 20 seconds – reduced to 50μg for the RCA). In order to assess 
non-endothelial dependent vasodilatation, 300 µg of GTN was administered by manual 



































































6. Angiographic analysis and quantitative coronary
angiography (QCA) 
Quantitative coronary analysis of the target coronary artery was performed using 
computer-assisted angiographic analysis (QAngio XA7.3, Medis, Leiden, Netherlands) 
by a trained cardiologist. Fluoroscopic images from two angles at least 30° apart were 
acquired. The coronary artery (typically left anterior descending artery) measurements 
were performed in the region where the greatest change had occurred during coronary 
reactivity testing.10 End-diastolic cine frames that best show the segment were selected, 
and calibration of the video and cine images was performed. Coronary artery diameter 
change (% from baseline) was measured in response to both ACh and glyceryl trinitrate. 
Severe endothelial dysfunction was defined by ≥20% luminal constriction during ACh 
infusion (up to 10−4M); this finding implies significant reduction in coronary artery blood 
flow with prognostic implications when compared with patients whose arteries were 
<20% constricted.11 Coronary artery disease severity was assessed using the Gensini 
score.12A second trained observer (PM) performed QCA on a consecutive sample of 10% 
of cases, with high concordance for measurements of percentage lumen diameter 
vasoconstriction during ACh vasospasm assessment (intraclass correlation coefficient for 
average measures 0.96; 95% CI 0.88-0.99; p<0.001) and Gensini angiographic score 




































































7. Definitions: coronary microvascular dysfunction
We defined CMD using invasive coronary function testing and the Coronary Vasomotion 
Disorders International Study Group (COVADIS) diagnostic criteria.13 These 
physiological criteria included raised IMR, abnormal coronary vasodilator capacity 
(CFR) and/or microvascular spasm during ACh provocation (reproduction of angina 
symptoms, ischaemic ECG changes (≥1mm ST segment deviation), but < 90% epicardial 
spasm during ACh testing).14 FFR was measured to rule-out flow limiting coronary artery 
disease as an alternative explanation for myocardial ischaemia. Therefore, all participants 




































































8. Blood and tissue analysis
Serum ET-1 was determined using blood obtained on the day of coronary function testing 
(Quantikine ® ELISA, R&D Systems® Europe, Abington [UK]). Blood was obtained 
from participants following an overnight fast in a recumbent position. 
Ex vivo pharmacological assessment of peripheral vascular function was performed on 
patients who volunteered to undergo a gluteal skin fat biopsy within 4 weeks of the 
invasive coronary function assessment. The biopsy was obtained under sterile conditions 
using local anaesthesia with lidocaine (2%). Arterioles (< 400µm) were carefully 
dissected from fresh biopsies using a light microscope. 2mm length arterioles were 
mounted on 40-μm stainless steel wires for isometric myography in multi-channel 
myograph chambers (DMT, Denmark) filled with physiological saline solution. Isometric 
tension recordings followed-on directly using the technique of wire myography to study 
small peripheral resistance arteries with paired cumulative concentration response curves 
(CCRCs) to ET-1 in the presence or absence of an ETA receptor antagonist, either BQ123 
or zibotentan. The detailed methods are described in the study appendix. The peripheral 
vascular sensitivity to ET-1 (pEC50) and maximum vasoconstriction to ET-1 (Emax) were 
determined. 
For the antagonist studies the affinity (KB) of BQ123 was first determined in paired 
vessels from individuals and calculated using Schild regression. The pKB (-log10 KB) 
values were compared between each genotype as an indicator of whether or not patients 
of different genotypes are likely to respond equally well to an ETA antagonist used 



































































CCRCs in the presence and absence of a highly selective ETA receptor antagonist, 
zibotentan to determine a pKB value. More importantly the aim of these experiments was 




































































9. DNA extraction and genotyping
Buffy coat was extracted from the whole blood of patients after centrifugation at 
10,000g) to isolate genomic DNA using The PureLink® Genomic DNA Mini Kit 
(Invitrogen™). The samples were added to the lysis/binding buffer and digested with 
Proteinase K and RNase A for a minimum of 10 minutes at 50oC. The samples were then 
brought to room temperature, followed by the addition of absolute ethanol. This was 
applied to the PureLink® Spin column and centrifuged, followed by subsequent washing 
and elution using Tris EDTA buffer. The quantity and quality of the DNA extracted was 
determined using NanoDrop™ Lite Spectrophotometer (ThermoFisher Scientific™). 
To determine the genotype for rs9349379, the probes TaqMan® SNP Genotyping Assay 
ID C___1756707_10, with the context Sequence [VIC/FAM]: 
TCTATGCCCTTGAGATCATATAAAA[A/G]TAGCTTAAAATCATTGGCCATAGT
T (Applied Biosystems™). DNA concentration of 5ng/uL was used with the TaqMan® 
probes and TaqMan® Universal Master Mix II, no UNG (Applied Biosystems™) to a 
total reaction volume of 5uL. This was amplified and read using QuantStudio™ 12K Flex 



































































10. Cardiac magnetic resonance imaging and ischaemia 
testing protocol 
Patients were invited to undergo quantitative perfusion cardiac magnetic resonance 
(CMR) imaging at 1.5 Tesla using pharmacological stress testing with intravenous 
adenosine (140 µg/kg/min) within 6 weeks of the index coronary angiogram. CMR 
studies were performed using a standardized CMR protocol (Siemens MAGNETOM 
Avanto, Erlangen, Germany). Qualitative review for an inducible subendocardial 
perfusion defect consistent with microvascular dysfunction was independently performed 
by two cardiologists blinded to patient genotype. Quantitative measurement of the 
myocardial perfusion reserve ratio using a novel pixel-mapping technique was also 
performed (Supplementary information). Treadmill exercise stress electrocardiography 
using the Bruce protocol was analysed from the sub-group of patients who had been pre-
selected for this procedure on clinical grounds prior to invasive coronary angiography. 
The exercise ECG parameters including (1) exercise duration and (2) the Duke Treadmill 
Score15 were analysed by a cardiology researcher (EY) blinded to genotype and invasive 
physiology. 
All subjects were asked to abstain from caffeine-containing beverages or foodstuffs for 
24 hours, and vasoactive medications for 48 hours prior to the CMR examination. All 
scan acquisitions were spatially co-registered. All CMR analyses were performed by a 




































































Stress and rest first-pass perfusion imaging were performed using an echo planar imaging 
(EPI) dual-sequence investigational perfusion method, which consists of a low resolution 
arterial input function (AIF) image, followed by three short axis (base, mid, apex) 
myocardial images during each R-R interval.16-18 First-pass perfusion images were 
obtained in 3 LV short-axis slices and one long-axis slice. Vasodilator stress was 
achieved with adenosine infusion 140-210 µg/kg/min for 3 minutes. Resting first-pass 
perfusion was performed at least 10 minutes later. 
The raw stress and rest perfusion images were qualitatively assessed for inducible or 
fixed perfusion defects. The perfusion was classified as either normal, abnormal, or 
equivocal. If a perfusion defect was present, it was reported as having and epicardial, 
microvascular or equivocal pattern. Normal myocardial perfusion was depicted by 
homogeneous first pass perfusion as revealed by dynamic first pass perfusion imaging 
and the pixel maps. An inducible perfusion defect on dynamic first pass imaging during 
adenosine hyperaemia was reflected by a relative reduction in myocardial signal intensity 
notably in the sub-endocardium extending radially. The onset of the defect would occur 
with the arrival of the gadolinium contrast media in the left ventricular blood pool, it 
would persist beyond peak myocardial enhancement for 5 or more R-R intervals, and 
regresses over time towards the sub-endocardium. The defect would be present during 
stress but not resting conditions. The defect may conform to the myocardial blood supply 
of an epicardial coronary artery in a transmural distribution, or if the defect is primarily 
due to microvascular disease, the defect may be circumferential and restricted to the sub-



































































perfusion abnormality would meet some but not all of these criteria, raising a suspicion of 
a perfusion abnormality but not clearly diagnostic. Perfusion defects were reported on a 
segmental basis according to the American Heart Association 16-segment model.20 Dark 
banding artefact was adjudicated based on standardised criteria.19 
Pixel-wise perfusion maps were generated and analysed to derive fully quantitative MBF 
estimates on a pixel-wise basis in ml/g/min of myocardium. The pixel-wise perfusion 
method used a series of automated post-processing steps on the raw Digital Imaging and 
Communications in Medicine (DICOM) images to generate fully quantitative pixel maps. 
The pixel-wise time-signal intensity curves were then quantified using model-constrained 
Fermi deconvolution.21-23 
Extra-cardiac anatomy and LV volumes, function and mass 
Fast gradient echo ‘white-blood’ images in the axial, coronal and sagittal planes were 
obtained, and were qualitatively assessed for extra-cardiac anatomy and pathology, and 
clinically-relevant incidental findings. 
Steady-state free procession (SSFP) ‘cine’ imaging using a trueFISP sequence (multi-
slice single-shot breath-hold true fast imaging) was performed in the 3 long-axis planes 
and short axis cine ‘stack’ for assessment of LV volumes, function and mass. 
Myocardial tissue characterisation 
Native T1 mapping was performed using a modified look-locker inversion-recovery 
(MOLLI) investigational prototype sequence. Images were obtained in three short-axis 



































































assess the myocardial native T1 relaxation time and estimate the myocardial extracellular 
volume (ECV) in both the mid-septum and globally.24 
Late gadolinium enhancement imaging was performed using a segmented phase-sensitive 
inversion recovery (PSIR) turbo fast low-angle shot imaging sequence.25 Images were 
obtained in the three long-axis planes and short-axis images covering the entire left 
ventricle. The pattern and burden of hyper-enhancement was both qualitatively and 
quantitatively assessed. 
11. Peripheral vascular function assessment
Competition binding study in human heart to confirm ETA selectivity of zibotentan 
Initial reports on the pharmacology of zibotentan demonstrated that the compound had 
high affinity for the human cloned ETA receptor (21 nmol/L) and no detectable affinity at 
human cloned ETB receptors.
26  We have confirmed ETA selectivity in human heart, a 
tissue that expresses both ETA and ETB receptors. 
Briefly, human heart was collected with informed patient consent and local ethical 
approval.  Competition binding experiments (n=3) were performed in cryostat-cut frozen 
heart sections (10μm) with [125I]ET-1 (0.1nM) in the presence of increasing 
concentrations of zibotentan (2 pmol/L-100 μmol/L). Non-specific binding was 
determined using 1μol/L ET-1.  Data were analysed to obtain affinity, pKi (the –log10of 
the equilibrium dissociation constant Ki determined in a competition binding assay), for 



































































biphasic manner (Supplementary Figure 2) resulting in a pKiSEM for the ETA receptor 
of 9.880.13 and for the ETB receptor of 4.020.04 indicating a >720,000 fold selectivity 
for the human ETA compared to the human ETB receptor in heart. 
Experiments were designed to investigate whether patients with the SNP G allele, who 
had therefore been exposed to higher levels of endogenous endothelin-1 (ET-1), exhibited 
a change in responsiveness of vascular smooth ETA receptors assessed in vitro.  Initial 
studies determined whether there was evidence of endothelial dysfunction, indicated by a 
change in either potency or maximum response to the endothelium-dependent vasodilator 
acetylcholine (Ach) or whether the response to ET-1 was altered and if changes for either 
compound correlated to whether individuals expressed the SNP G allele or not.  Finally, 
it was important to establish that, whatever the underlying genotype, responses to ET-1 
could be blocked by ETA antagonists.  Two antagonists were tested.  The very well 
characterised peptide antagonist BQ123 and importantly the orally active, highly 
selective ETA antagonist zibotentan that has the potential to be rapidly repurposed for 
clinical use in this patient group. 
Preparation of small resistance arteries 
Vessels were dissected from a gluteal skin fat biopsy (approximately 3 x 2 x 2 cm) 
performed within 4 weeks of coronary angiography. Vasoactive medications were 
withheld for at least 24 hours prior to the surgical biopsy. Small resistance arterioles 



































































myograph (Danish Myotech, Aarhus, Denmark) with isometric tension recordings made 
as previously described.27 
Experimental Protocol 
After a standard normalisation and start-up protocol involving repeated washes with high 
potassium chloride solution (62.5 mmol/L KPSS), the arterioles were pre-constricted with 
the thromboxane-A2 analogue, U46619 (0.1 mol/L). Previous work on human 
resistance arteries support its application in myography due to its consistent 
vasoconstriction with a steady plateau from which to assess arteriolar relaxation. Blood 
vessels with no responses were discarded.  For viable tissue the integrity of the 
endothelium was determined by constructing a cumulative concentration-response curve 
(CCRC) to ACh (1n mol/L - 1µ mol/L).  CCRCs were then obtained to the 
vasoconstrictor peptide ET-1(1 p mol/L - 1 μmol/L). 
For relaxation data, responses to ACh were expressed as the percentage reversal of the 
constrictor response to U46619 (100nmol/L). Data for ET-1 were normalised as a 
percentage of the mean response to the last two responses to 62.5mol/L potassium 
chloride obtained during the set up procedure.  CCRCs were fitted using four‐parameter, 
non‐linear regression curve fitting in Prism 7.0 (GraphPad Inc, La Jolla, CA, USA) to 
obtain values of potency (expressed as the pEC50, that is the –log10 of the EC50 (the 
concentration producing half-maximal response)) and maximum response (Emax) for both 




































































For antagonist studies paired tissues from patients were used to construct CCRCs to ET-1 
in either the absence (control) or presence of 1 µmol/L BQ123 (N=27) or 1µmol/L 
zibotentan (N=8).  Data were expressed as % KPSS as described above and paired 
CCRCs were then analysed using the Gaddum/Schild EC50 equation (GraphPad Prism).  
The Hill and Schild slopes were constrained to 1 and therefore antagonist affinity was 
given as the pKB (the –log10 of the equilibrium dissociation constant).  pKB values for 
BQ123 derived from individuals with different SNP alleles were compared. 
Finally, vessels from some individuals were preconstricted with ET-1 and the constrictor 
response allowed to stabilise before addition of either no antagonist (time matched 
control ) or 0.1µmol/L or 1µmol/L zibotentan was added.  The contraction to ET-1 was 





































































Pharmacology definitions: potency (pEC50) is the –log10 of the concentration of a drug 
that gives half-maximal response; Efficacy is given as Emax, the % contraction to KPSS; 
pKB is the –log10 of the antagonist affinity (KB the equilibrium dissociation constant of 
the antagonist for the ETA receptor). For wire myography, we analysed pKB between 
three groups using one-way ANOVA and adopted a two-tailed model with alpha of 0.05 
and beta of 0.2 giving a planned power of 80%. An estimated effect size (f) of 0.544 was 
determined using estimated group mean pKB values of 7.7, 7.6 and 7.5 respectively (SD 
of 0.15). A minimum sample size of 36 subjects was determined using G*Power 3.1 
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